Part Part 2 - Health Insurance (1999-2000 Pathology Services Table) Regulations 1999 - Services and fees

Part 2 Services and fees
Category 6 Pathology services
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse"><thead><tr><td colspan="2" style="width:53.4pt; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="font-size:10pt"><span>Item</span></p></td><td style="width:244.45pt; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="font-size:10pt"><span>Pathology service</span></p></td><td style="width:38.65pt; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="font-size:10pt"><span>Fee</span><span> </span><span></span><span></span><span>($)</span></p></td></tr></thead><tbody><tr><td colspan="4" style="width:357.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="font-size:10pt"><span>Group P1</span><span> </span><span>— Haematology</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65060</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Haemoglobin, erythrocyte sedimentation rate, blood viscosity</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>7.70</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65063</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Erythrocyte count, haematocrit, haemoglobin, calculation or measurement of red cell index or indices, platelet count, leucocyte count and instrument generated differential count</span><span> </span><span>— not being a service where haemoglobin only is requested</span><span> </span><span>— including any services in item 65060 or 65072</span><span> </span><span>— 1 or more instrument generated results from a single sample</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>16.70</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65066</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Examination of:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>a blood film by special stains to demonstrate Heinz bodies, parasites or iron; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>a blood film by enzyme cytochemistry for neutrophil alkaline phosphatase, alpha</span><span>‑</span><span>naphthyl acetate esterase or chloroacetate esterase; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>a blood film using any other special staining methods including periodic acid Schiff and Sudan Black; or</span></p><p class="paratable"><span>(d)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>a urinary sediment for haemosiderin; including a service described in item 65072</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.25</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65069</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Full blood examination consisting of:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>a morphological assessment of a blood film; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>item 65063; and</span></p><p class="paratable"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any test in item</span><span> </span><span>65060 or 65072</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>16.70</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65072</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination for reticulocytes including a reticulocyte count by any method</span><span> </span><span>— 1 or more tests in any episode</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65075</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Haemolysis or metabolic enzymes</span><span> </span><span>— assessment by:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>erythrocyte autohaemolysis test; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>erythrocyte osmotic fragility test; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>sugar water test; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(d)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>G</span><span>‑</span><span>6</span><span>‑</span><span>P D (qualitative or quantitative) test; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(e)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>pyruvate kinase (qualitative or quantitative) test; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(f)</span><span style="width:14.81pt; text-indent:0pt; display:inline-block"> </span><span>acid haemolysis test; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(g)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>quantitation of muramidase in serum or urine; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(h)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>Donath Landsteiner antibody test; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(i)</span><span style="width:15.42pt; text-indent:0pt; display:inline-block"> </span><span>other erythrocyte metabolic enzyme tests;</span></p><p class="TableText" style="margin-top:3pt"><span>1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>51.30</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65078</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Tests for the diagnosis of thalassaemia when indicated on the basis of an abnormal full blood examination or by the clinical need for family studies, consisting of haemoglobin electrophoresis or chromatography and at least 2 of:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>examination for HbH; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>quantitation of HbA2; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>quantitation of HbF;</span></p><p class="TableText" style="margin-top:3pt"><span>including (if performed) any service described in item</span><span> </span><span>65060, 65063 or 65069</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>89.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65081</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Tests for the investigation of haemoglobinopathy (including S, C, D, E), other than thalassaemia, when indicated on the basis of an abnormal full blood examination or by the clinical need for family studies, consisting of haemoglobin electrophoresis or chromatography and at least 1 of:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>heat denaturation test; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>isopropanol precipitation test; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>tests for the presence of haemoglobin S; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(d)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>quantitation of any haemoglobin fraction (including S, C, D, E);</span></p><p class="TableText" style="margin-top:3pt"><span>including (if performed) any service described in item</span><span> </span><span>65060, 65063, 65069 or 65078</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>95.30</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65084</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Bone marrow trephine biopsy</span><span> </span><span>— histopathological examination of sections of bone marrow and examination of aspirated material (including clot sections where necessary), including (if performed):</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>special stains or immunohistochemical techniques (if any); and</span></p><p class="paratable"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>any test described in item 65060, 65063, 65066 or 65069</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>163.70</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65087</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Bone marrow</span><span> </span><span>— examination of aspirated material (including clot sections where necessary), including (if performed):</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>special stains or immunohistochemical techniques (if any); and</span></p><p class="paratable"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>any test described in item 65060, 65063, 65066 or 65069</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>82.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65090</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Blood grouping (including back</span><span>‑</span><span>grouping if performed)</span><span> </span><span>— ABO and Rh (D antigen)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.90</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65093</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Blood grouping</span><span> </span><span>— Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system</span><span> </span><span>— 1 or more systems, including item 65090 (if performed)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>21.70</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65096</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Blood grouping (including back</span><span>‑</span><span>grouping if performed), and examination of serum for Rh and other blood group antibodies, including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>identification and quantitation of any antibodies detected; and</span></p><p class="paratable"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any test described in item</span><span> </span><span>65060, 65063 or 65069</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.40</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65099</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Compatibility tests by crossmatch</span><span> </span><span>— all tests performed on any one day for up to 6 units, including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>all grouping checks of the patient and donor; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>examination for antibodies, and if necessary identification of any antibodies detected; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any tests described in item</span><span> </span><span>65060, 65063, 65069, 65090 or 65096</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule</span><span> </span><span>5)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>110.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65102</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Compatibility tests by crossmatch</span><span> </span><span>— all tests performed on any one day in excess of 6 units, including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>all grouping checks of the patient and donor; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>examination for antibodies, and if necessary identification of any antibodies detected; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any tests described in item</span><span> </span><span>65060, 65063, 65069, 65090, 65096, 65099 or 65105</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 5)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>165.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65105</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion</span><span> </span><span>— all tests performed on any one day for up to 6 units, including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>all grouping checks of the patient and donor; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>examination for antibodies and, if necessary, identification of any antibodies detected; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any tests described in item</span><span> </span><span>65060, 65063, 65069, 65090 or 65096</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 5)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>110.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65108</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion</span><span> </span><span>— all tests performed on any one day in excess of 6 units, including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>all grouping checks of the patient and donor; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>examination for antibodies and, if necessary, identification of any antibodies detected; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any tests described in item</span><span> </span><span>65060, 65063, 65069, 65090, 65096, 65099 or 65105</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 5)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>165.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65111</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>22.90</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65114</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>1 or more of the following tests:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>direct Coombs (antiglobulin) test;</span></p><p class="paratable"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>qualitative or quantitative test for cold agglutinins or heterophil antibodies</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>8.95</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65117</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>1 or more of the following tests:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>qualitative spectroscopic examination of blood for chemically altered haemoglobins;</span></p><p class="paratable"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>detection of methaemalbumin (Schumm’s test)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65120</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-right:2pt"><span>Prothrombin time (including INR where appropriate), activated partial thromboplastin time, thrombin time (including test for the presence of heparin), test for factor XIII deficiency (qualitative), Echis test, Stypven test, reptilase time, fibrinogen, or 1 of fibrinogen degradation products, fibrin monomer or D</span><span>‑</span><span>dimer</span><span> </span><span>— 1</span><span> </span><span>test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.65</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65123</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 65120</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65126</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 tests described in item 65120</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>27.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65129</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>4 or more tests described in item 65120</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>35.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65132</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Test for the presence of antithrombin</span><span> </span><span>III deficiency, protein C deficiency, protein S deficiency, lupus anticoagulant, activated protein C resistance, if the request for the test specifically identifies in writing a history of venous thromboembolism or arterial thrombosis</span><span> </span><span>— 1 test involving quantitation by 1 or more techniques</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65133</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item</span><span> </span><span>65132</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>48.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65134</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 tests described in item</span><span> </span><span>65132</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>71.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65135</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>4 tests described in item</span><span> </span><span>65132</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>94.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65136</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>5 tests described in item</span><span> </span><span>65132</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>117.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65137</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Test for the presence of lupus anticoagulant, not being a service connected with a service to which item 65132 applies</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65139</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of plasminogen</span><span> </span><span>— 1 test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65140</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of euglobulin clot lysis time</span><span> </span><span>— 1 test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65142</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Confirmation or characterisation of an abnormal or an indeterminate result of a test, or tests, mentioned in item</span><span> </span><span>65132, using a separate specimen collected on a different day</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65144</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or other substances; or heparin, low molecular weight heparins, heparinoid or other drugs</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>55.80</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65147</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of anti</span><span>‑</span><span>Xa activity when monitoring is required for a patient receiving a low molecular weight heparin or heparinoid</span><span> </span><span>— 1 test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>37.40</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65150</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of von Willebrand factor antigen, von Willebrand factor activity (ristocetin cofactor assay), von Willebrand factor collagen binding activity, factor</span><span> </span><span>II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor</span><span> </span><span>XIII, Fletcher factor, Fitzgerald factor, circulating coagulation factor inhibitors other than by Bethesda assay</span><span> </span><span>— 1 test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>70.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65153</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 65150</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>140.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65156</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 65150</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>210.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65159</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of circulating coagulation factor inhibitors by Bethesda assay</span><span> </span><span>— 1 test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>70.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65162</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of a maternal blood film for the presence of fetal red blood cells (Kleihauer test)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.25</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65165</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection and quantitation of fetal red blood cells in the maternal circulation by detection of red cell surface antigens using flow cytometric methods including (if performed) any test described in item</span><span> </span><span>65069 or 65162</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65168</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of the genotype of a patient for Factor V Leiden gene mutation, or detection of other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65171</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency or activated protein C resistance in a first degree relative of a person who has a proven deficiency mentioned in this item</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65174</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of the genotype of a person who is a first degree relative of a person who has been proven to have 1 or more abnormal genotypes under item</span><span> </span><span>65168</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.00</span></p></td></tr><tr><td colspan="4" style="width:357.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="page-break-after:avoid"><span>Group P2</span><span> </span><span>— Chemical</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66500</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation in serum, plasma, urine or other body fluid (except amniotic fluid), by any method except reagent tablet or reagent strip (with or without reflectance meter or electrophoresis) of: acetoacetate, acid phosphatase, alanine aminotransferase, albumin, alkaline phosphatase, ammonia, amylase, aspartate aminotransferase, beta-hydroxybutyrate, bicarbonate, bilirubin (total), bilirubin (any fractions), C-reactive protein, calcium (total or corrected for albumin), chloride, creatine kinase, creatinine, gamma glutamyl transferase, globulin, glucose, lactate, lactate dehydrogenase, lipase, magnesium, phosphate, potassium, pyruvate, sodium, total protein, urate or urea</span><span> </span><span>— 1 test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66503</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 66500</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66506</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 tests described in item 66500</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66509</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>4 tests described in item 66500</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66512</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>5 tests described in item 66500</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66515</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>6 or more tests described in item 66500</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66518</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Investigation of cardiac or skeletal muscle damage by measurement of creatine kinase isoenzymes (by any method), troponin or myoglobin in plasma or serum</span><span> </span><span>— 1 or more tests in a 24 hour period</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.80</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66521</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation (except by reagent strip with or without reflectance meter or electrophoresis) of cholesterol or triglycerides or both in serum, plasma, urine or other body fluid</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.40</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66524</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A service described in item 66521 and 1 test described in item 66500</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66527</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A service described in item 66521 and 2 tests described in item 66500</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66530</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A service described in item 66521 and 3 tests described in item 66500</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66533</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A service described in item 66521 and 4 or more tests described in item 66500</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66536</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Quantitation of HDL cholesterol or apolipoprotein B/A1 ratio in a patient who:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>has a serum cholesterol level &gt;5.5mmol/L; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>has a fasting serum triglyceride level &gt;2.0</span><span> </span><span>mmol/L; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>is on a lipid lowering drug prescribed by a medical practitioner;</span></p><p class="TableText" style="margin-top:3pt; margin-bottom:3pt"><span>each episode to a maximum of 4</span><span> </span><span>episodes in a 12</span><span> </span><span>month period</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 9)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.40</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66539</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Electrophoresis of serum for demonstration of lipoprotein subclasses, if the cholesterol is &gt;6.5</span><span> </span><span>mmol/L and triglyceride &gt;4.0 mmol/L or in the diagnosis of types III and IV hyperlipidaema</span><span> </span><span>— each episode to a maximum of 2</span><span> </span><span>episodes in a 12</span><span> </span><span>month period</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.20</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66542</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Oral glucose tolerance test for the diagnosis of diabetes mellitus, that includes:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>administration of glucose; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>at least 2 measurements of blood glucose; and</span></p><p class="paratable"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any test described in item</span><span> </span><span>66695</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>18.70</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66545</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Oral glucose challenge test in pregnancy for the detection of gestational diabetes that includes:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>administration of glucose; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>1 or 2 measurements of blood glucose; and</span></p><p class="paratable"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any test in item 66695</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.60</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66548</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Oral glucose tolerance test in pregnancy for the diagnosis of gestational diabetes that includes:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>administration of glucose; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>at least 3 measurements of blood glucose; and</span></p><p class="TableText" style="margin-top:3pt; margin-left:25.8pt; text-indent:-25.8pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any test in item 66695</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.70</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66551</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of glycosylated haemoglobin performed in the management of established diabetes</span><span> </span><span>— each test to a maximum of 4 tests in a 12 month period</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>16.60</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66554</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of glycosylated haemoglobin performed in the management of pre-existing diabetes where the patient is pregnant</span><span> </span><span>— each test to a maximum of 6</span><span> </span><span>tests in a 12 month period which includes the whole pregnancy, including a service in item 66551 (if performed)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>16.60</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66557</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of fructosamine performed in the management of established diabetes</span><span> </span><span>— each test to a maximum of 4 tests in a 12 month period</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.55</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66560</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microalbumin in proven diabetes mellitus</span><span> </span><span>— quantitation in urine</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.90</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66563</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Osmolality, estimation by osmometer, in serum or in urine</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.35</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66566</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Quantitation of:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>blood gases (including pO</span><span style="font-size:8pt; vertical-align:-2pt">2</span><span>, oxygen saturation and pCO</span><span style="font-size:8pt; vertical-align:-2pt">2</span><span>); and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>bicarbonate and pH;</span></p><p class="TableText" style="margin-top:3pt"><span>including any other measurement (eg haemoglobin, potassium or ionised calcium) or calculation performed on the same specimen</span><span> </span><span>— 1</span><span> </span><span>or more tests on 1</span><span> </span><span>specimen</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>33.25</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66569</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 2 specimens performed within any 1 day</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>42.05</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66572</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 3 specimens performed within any 1 day</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>50.85</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66575</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 4 specimens performed within any 1 day</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>59.65</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66578</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 5 specimens performed within any 1 day</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>68.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66581</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 6 or more specimens performed within any 1 day</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>77.25</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66584</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of ionised calcium (except if performed as part of item 66566)</span><span> </span><span>— 1 test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.55</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66587</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Urine acidification test for the diagnosis of renal tubular acidosis including the administration of an acid load, and pH measurements on 4 or more urine specimens and at least 1 blood specimen</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>46.90</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66590</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Calculus, analysis of 1 or more</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.20</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66593</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Ferritin</span><span> </span><span>— quantitation, except if requested as part of iron studies</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>18.80</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66596</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Iron studies, consisting of quantitation of:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>serum iron; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>transferrin or iron binding capacity; and</span></p><p class="paratable"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>ferritin</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.10</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66599</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Serum B12 or red cell folate and, if required, serum folate</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 22)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.35</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66602</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Serum B12 and red cell folate and, if required, serum folate</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 22)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>44.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66605</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Vitamins</span><span> </span><span>— quantitation of vitamins A, B1, B2, B3, B6, C and E in blood, urine or other body fluid</span><span> </span><span>— 1 or more tests within a 6 month period</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.20</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66608</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Vitamin D or D fractions</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>41.70</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66611</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Quantitation, not elsewhere described in this table by any method or methods, in blood or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken</span><span> </span><span>— 1</span><span> </span><span>test</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66614</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>2 tests described in item 66611</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>32.60</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66617</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>3 or more tests described in item 66611</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>44.80</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66620</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Tests described in item 66611, if rendered under a request referred to in subparagraph (2)</span><span> </span><span>(a)</span><span> </span><span>(iii) of rule</span><span> </span><span>6</span><span> </span><span>— each test to a maximum of 2 tests</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>12.20</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66623</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>All qualitative and quantitative tests on blood, urine or other body fluid for:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>ingested or absorbed toxic chemicals;</span></p><p class="TableText" style="margin-top:3pt; margin-bottom:3pt"><span>including a service described in item 66611, 66614 or</span><span> </span><span>66617 (if performed), but excluding:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the surveillance of sports people and athletes for performance improving substances; and</span></p><p class="paratable"><span>(d)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>the monitoring of patients participating in a drug abuse treatment program</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>41.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66626</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Detection or quantitation or both (not including the detection of nicotine and metabolites in smoking withdrawal programs) of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a patient:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>participating in a drug abuse treatment program; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>being monitored for drug effects;</span></p><p class="TableText" style="margin-top:3pt; margin-bottom:3pt"><span>but excluding the surveillance of sports people and athletes for performance improving substances;</span></p><p class="TableText" style="margin-top:3pt"><span>including all tests on blood, urine or other body fluid</span><span> </span><span>— each episode, to a maximum of 21</span><span> </span><span>episodes in a 12 month period</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>23.80</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66629</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Beta-2-microglobulin</span><span> </span><span>— quantitation in serum, urine or other body fluids</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.90</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66632</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Caeruloplasmin, haptoglobins, or prealbumin</span><span> </span><span>— quantitation in serum, urine or other body fluids</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.90</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66635</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Alpha</span><span>‑</span><span>1</span><span>‑</span><span>antitrypsin — quantitation in serum, urine or other body fluid</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.90</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66638</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Isoelectric focussing or similar methods for determination of alpha</span><span>‑</span><span>1</span><span>‑</span><span>antitrypsin phenotype in serum</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.80</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66641</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Electrophoresis of serum or other body fluid to demonstrate:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the isoenzymes of lactate dehydrogenase; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>the isoenzymes of alkaline phosphatase;</span></p><p class="TableText" style="margin-top:3pt"><span>including the preliminary quantitation of total relevant enzyme activity</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.80</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66644</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>C-1 esterase inhibitor</span><span> </span><span>— quantitation</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.90</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66647</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>C-1 esterase inhibitor</span><span> </span><span>— functional assay</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>44.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66650</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Alpha</span><span>‑</span><span>fetoprotein, CA</span><span>‑</span><span>15.3 antigen (CA15.3), CA</span><span>‑</span><span>19.9 antigen (CA19.9), CA</span><span>‑</span><span>125 antigen (C125), cancer associated serum antigen (CASA), carcinoembryonic antigen (CEA), human chorionic gonadotrophin (HCG), mammary serum antigen (MSA), thyroglobulin in serum or other body fluid, in the monitoring of malignancy</span><span> </span><span>or in the detection or monitoring of gestational trophoblastic disease</span><span> </span><span>— quantitation</span><span> </span><span>— 1 test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66653</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 or more tests described in item 66650</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>44.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66656</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Prostate specific antigen or prostate acid phosphatase</span><span> </span><span>— quantitation in the confirmation or monitoring of malignancy</span><span> </span><span>— 1</span><span> </span><span>test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.90</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66659</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 66656</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.65</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66662</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>78.90</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66665</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Lead quantitation in blood or urine (other than for occupational health screening purposes) to a maximum of 3 tests in a 6 month period</span><span> </span><span>— each test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.20</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66668</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium, strontium, or zinc, in blood, urine or other body fluid or tissue</span><span> </span><span>— 1 or more tests in a 6</span><span> </span><span>month period</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>41.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66671</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of serum aluminium in a patient in a renal dialysis program</span><span> </span><span>— each test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.40</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66674</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Quantitation of:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>faecal fat; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>breath hydrogen in response to loading with disaccharides;</span></p><p class="TableText" style="margin-top:3pt"><span>1 or more tests within a 28 day period</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>39.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66677</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Test for tryptic activity in faeces in the investigation of diarrhoea of longer than 4 weeks duration in children under 6 years old</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66680</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of disaccharidases and other enzymes in intestinal tissue</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>73.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66683</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Enzymes</span><span> </span><span>— quantitation in solid tissue or tissues other than blood elements or intestinal tissue</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>73.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66686</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Performance of 1 or more of the following procedures:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>growth hormone suppression by glucose loading;</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>growth hormone stimulation by exercise;</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>dexamethasone suppression test;</span></p><p class="paratable" style="margin-bottom:3pt"><span>(d)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>sweat collection by iontophoresis for chloride analysis;</span></p><p class="paratable"><span>(e)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>pharmacological stimulation of growth hormone</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>50.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66689</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Personal performance by a recognised pathologist of 1</span><span> </span><span>of the following procedures:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>gonadotrophin releasing hormone stimulation test;</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>synacthen stimulation test;</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>glucagon stimulation test with C</span><span>‑</span><span>peptide measurement;</span></p><p class="paratable" style="margin-bottom:3pt"><span>(d)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>pentagastrin or calcium stimulation of thyrocalcitonin release;</span></p><p class="paratable" style="margin-bottom:3pt"><span>(e)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>secretin or calcium stimulation of gastrin release;</span></p><p class="paratable" style="margin-bottom:3pt"><span>(f)</span><span style="width:14.81pt; text-indent:0pt; display:inline-block"> </span><span>insulin hypoglycaemia;</span></p><p class="paratable" style="margin-bottom:3pt"><span>(g)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>arginine infusion;</span></p><p class="paratable"><span>(h)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>thyrotrophin releasing hormone (TRH) test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>80.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66692</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Personal performance by a recognised pathologist of 2</span><span> </span><span>or more tests described in item 66689</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>140.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66695</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of hormones and hormone binding proteins</span><span> </span><span>— ACTH, aldosterone, androstenedione, C</span><span>‑</span><span>peptide, calcitonin, cortisol, cyclic AMP, DHEAS, 11-deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(IGF</span><span> </span><span>‑</span><span>1), free or total testosterone, urine steroid fraction or fractions, vasoactive intestinal peptide, vasopressin (antidiuretic hormone)</span><span> </span><span>— 1 test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>31.30</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66698</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>2 tests described in item 66695</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>44.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66701</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>3 tests described in item 66695</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>57.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66704</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>4 tests described in item 66695</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>70.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66707</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>5 tests described in item 66695</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>83.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66710</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>6 or more tests described in item 66695</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>96.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66713</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Tests described in item 66695, if rendered under a request referred to in subparagraph (2)</span><span> </span><span>(a)</span><span> </span><span>(iii) of rule</span><span> </span><span>6</span><span> </span><span>— each test to a maximum of 5 tests</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66716</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>TSH quantitation</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.70</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66719</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Thyroid function tests (comprising the service described in item 66716 and 1 or more of the following tests</span><span> </span><span>— estimation of free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin) for a patient, if at least 1 of the following conditions is satisfied:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the patient has an abnormal level of TSH;</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>the tests are performed:</span></p><p class="subparatable" style="margin-bottom:3pt"><span style="width:29.57pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:14.2pt; text-indent:0pt; display:inline-block"> </span><span>for the purpose of monitoring thyroid disease in the patient; or</span></p><p class="subparatable" style="margin-bottom:3pt"><span style="width:26.51pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:14.2pt; text-indent:0pt; display:inline-block"> </span><span>to investigate the sick euthyroid syndrome if the patient is an admitted patient; or</span></p><p class="subparatable" style="margin-bottom:3pt"><span style="width:23.46pt; text-indent:0pt; display:inline-block"></span><span>(iii)</span><span style="width:14.2pt; text-indent:0pt; display:inline-block"> </span><span>to investigate dementia or psychiatric illness of the patient; or</span></p><p class="subparatable" style="margin-bottom:3pt"><span style="width:24.07pt; text-indent:0pt; display:inline-block"></span><span>(iv)</span><span style="width:14.2pt; text-indent:0pt; display:inline-block"> </span><span>to investigate amenorrhoea or infertility of the patient;</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the medical practitioner who requested the tests suspects the patient has a pituitary dysfunction;</span></p><p class="paratable" style="margin-bottom:6pt"><span>(d)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>the patient is on drugs that interfere with thyroid hormone metabolism or function</span></p><p class="TableText"><span>(Item is subject to rule 10)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.40</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66722</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>TSH quantitation described in item 66716 and 1</span><span> </span><span>test described in item 66695</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.40</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66725</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>TSH quantitation described in item 66716 and 2</span><span> </span><span>tests described in item 66695</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>56.40</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66728</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>TSH quantitation described in item 66716 and 3</span><span> </span><span>tests described in item 66695</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>69.40</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66731</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>TSH quantitation described in item 66716 and 4</span><span> </span><span>tests described in item 66695</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>82.40</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66734</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>TSH quantitation described in item 66716 and 5</span><span> </span><span>tests described in item 66695</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>95.40</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66737</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Tests described in items 66716 and 66695, if rendered under a request mentioned in subparagraph (2)</span><span> </span><span>(a)</span><span> </span><span>(iii) of rule 6</span><span> </span><span>— each test to a maximum of 5 tests</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66740</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation, in pregnancy, of alpha-fetoprotein, human chorionic gonadotrophin, oestriol and any other substance to detect foetal abnormality, including a service described in 1 or more of items 66743, 66746, 73527 and 73529 (if performed)</span><span> </span><span>— 1 patient episode in a pregnancy</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>54.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66743</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of alpha-fetoprotein in serum or other body fluids during pregnancy except if requested as part of item 66740</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.90</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66746</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Human placental lactogen or oestriol-quantitation, except if requested as part of item 66740</span><span> </span><span>— 1 test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>31.55</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66749</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Amniotic fluid, spectrophotometric examination of, and quantitation of:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>lecithin/sphingomyelin ratio; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>palmitic acid, phosphatidylglycerol orlamellar body phospholipid; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>bilirubin, including correction for haemoglobin;</span></p><p class="TableText" style="margin-top:3pt"><span>1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>32.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66752</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of citrate, oxalate, total free fatty acids or amino acids including cysteine, homocysteine, cystine and hydroxyproline (except if performed as part of item 66773 or 66776)</span><span> </span><span>— 1</span><span> </span><span>test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.35</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66755</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 or more tests described in item 66752</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>38.30</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66758</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of angiotensin converting enzyme, or cholinesterase</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.35</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66761</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Test for reducing substances in faeces by any method (except reagent strip or dipstick)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66764</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Examination for faecal occult blood (including tests for haemoglobin and its derivatives in the faeces) by:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>an immunological method; and</span></p><p class="paratable"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>a chemical method (except reagent strip or dip stick);</span></p><p class="TableText" style="margin-top:0pt"><span>with a maximum of 3 examinations on specimens collected on separate days in a 28 day period</span><span> </span><span>— 1</span><span> </span><span>examination by both methods</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>8.80</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66767</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 examinations by both methods described in item</span><span> </span><span>66764 performed on separately collected and identified specimens</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.60</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66770</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 examinations by both methods described in item</span><span> </span><span>66764 performed on separately collected and identified specimens</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>26.40</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66773</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of products of collagen breakdown for the monitoring of patients with proven low bone mineral density, and if performed, a service described in item</span><span> </span><span>66752</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.35</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66776</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of products of collagen breakdown for the monitoring of patients with metabolic bone disease or Paget’s disease of bone, and if performed, a service described in item 66752</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.35</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66779</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Adrenaline, noradrenaline, dopamine, histamine, hydroxyindoleacetic acid (5HIAA), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), phenylacetic acid (PAA) or serotonin</span><span> </span><span>— quantitation</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>39.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66782</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Porphyrins or porphyrins precursors</span><span> </span><span>— detection in plasma, red cells, urine or faeces</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66785</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Porphyrins or porphyrins precursors</span><span> </span><span>— quantitation in plasma, red cells, urine or faeces</span><span> </span><span>— 1 test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>39.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66788</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Porphyrins or porphyrins precursors</span><span> </span><span>— quantitation in plasma, red cells, urine or faeces</span><span> </span><span>— 2 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>65.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66791</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Porphyrin biosynthetic enzymes</span><span> </span><span>— measurement of activity in blood cells or other tissues</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>73.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66794</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>the patient has a first degree relative with haemochromatosis; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 21)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.00</span></p></td></tr><tr><td colspan="4" style="width:357.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="page-break-after:avoid"><span>Group P3</span><span> </span><span>— Microbiology</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69300</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microscopy of wet film material other than blood, from 1 or more sites, obtained directly from a patient (not cultures) including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>differential cell count (if performed); or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>examination for dermatophytes; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>dark ground illumination; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(d)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>stained preparation or preparations using any relevant stain or stains;</span></p><p class="TableText" style="margin-top:3pt"><span>1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>12.20</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69303</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Culture and (if performed) microscopy to detect pathogenic micro</span><span>‑</span><span>organisms (including fungi but excluding viruses) from nasal swabs, throat swabs, eye swabs and ear swabs (excluding swabs taken for epidemiological surveillance), including (if performed):</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>the detection of antigens not elsewhere described in this table; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 69300;</span></p><p class="TableText" style="margin-top:3pt"><span>specimens from 1 or more sites</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>21.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69306</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microscopy and culture to detect pathogenic micro-organisms (including fungi but excluding viruses) from skin or other superficial sites, including (if performed):</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the detection of antigens not elsewhere specified in this table; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>a service described in items 69300, 69303, 69312, 69318 and 73810;</span></p><p class="TableText" style="margin-top:3pt"><span>1 or more tests on 1 or more specimens</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>33.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69309</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microscopy and culture to detect dermatophytes and other fungi causing cutaneous disease from skin scrapings, skin biopsies, hair and nails (excluding swab specimens) and including (if performed):</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the detection of antigens not elsewhere specified in this table; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>a service described in items 69300, 69303, 69306, 69312, 69318 and 73810;</span></p><p class="TableText" style="margin-top:3pt"><span>1 or more tests on 1 or more specimens</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>47.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69312</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microscopy and culture to detect pathogenic micro</span><span>‑</span><span>organisms (including fungi but excluding viruses) from urethra, vagina, cervix or rectum (except for faecal pathogens), including (if performed):</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the detection of antigens not elsewhere specified in this table; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>a service described in items 69300, 69303, 69306 and 69318;</span></p><p class="TableText" style="margin-top:3pt"><span>1 or more tests on 1 or more specimens</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>33.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69315</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microscopy and culture to detect pathogenic micro</span><span>‑</span><span>organisms and the detection of chlamydia from urethra, vagina, cervix or rectum and including (if performed):</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the detection of microbial antigens; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 69300, 69303, 69306, 69312, 69318, 69363, 69369, 69372, 69375 or 73810;</span></p><p class="TableText" style="margin-top:3pt"><span>1 or more tests on 1 or more specimens</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>64.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69318</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microscopy and culture to detect pathogenic micro</span><span>‑</span><span>organisms (including fungi but excluding viruses) from specimens of sputum (except when part of items 69324, 69327 and 69330), including (if performed):</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the detection of antigens not elsewhere specified in this table; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>a service described in items 69300, 69303, 69306 and 69312;</span></p><p class="TableText" style="margin-top:3pt"><span>1 or more tests on 1 or more specimens</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>33.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69321</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microscopy and culture of post-operative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro-organisms (including fungi but excluding viruses) involving aerobic and anaerobic cultures and the use of different culture media, and including (if performed):</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>the detection of antigens not elsewhere specified in this table; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 69300, 69303, 69306, 69312 or 69318;</span></p><p class="TableText" style="margin-top:3pt"><span>specimens from 1 or more sites</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>47.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69324</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microscopy (with appropriate stains) and culture for mycobacteria</span><span> </span><span>— 1</span><span> </span><span>specimen of sputum, urine or other body fluid or 1</span><span> </span><span>operative or biopsy specimen, including (if performed):</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or</span></p><p class="paratable" style="margin-bottom:6pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing;</span></p><p class="TableText"><span>including a service mentioned in item 69300</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>42.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69330</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microscopy with appropriate stains and culture of 3</span><span> </span><span>specimens of sputum, urine, other body fluids or operative or biopsy specimens for mycobacteria including (if performed):</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>microscopy and culture of other bacterial pathogens; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing;</span></p><p class="TableText" style="margin-top:3pt"><span>including</span><span style="font-weight:bold"> </span><span>a service described in item 69300</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>125.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69333</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Urine examination (including serial examination) by any means other than simple culture by dip slide, including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>cell count; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>culture; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>colony count; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(d)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) stained preparations; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(e)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) identification of cultured pathogens; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(f)</span><span style="width:14.81pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) antibiotic susceptibility testing; and</span></p><p class="paratable"><span>(g)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.10</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69336</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy of faeces for parasites using concentration techniques (including the use of appropriate stains) with no more than 3</span><span> </span><span>examinations on specimens collected on separate days in any 7 day period, including (if performed) a test mentioned in item 69300</span><span> </span><span>— 1 examination</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>18.65</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69339</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 examinations described in item 69336 performed on separately collected and identified specimens</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>37.25</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69342</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 examinations described in item 69336 performed on separately collected and identified specimens</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>55.90</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69345</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Culture of faeces for faecal pathogens, using at least 2</span><span> </span><span>selective or enrichment media and culture in at least 2 different atmospheres including (if performed):</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>the detection of clostridial toxins or antigens not elsewhere specified in this table; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 69300;</span></p><p class="TableText" style="margin-top:3pt"><span>with a maximum of 3 examinations performed on separately collected and identified specimens in any 7</span><span> </span><span>day period</span><span> </span><span>— 1</span><span> </span><span>examination</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>51.65</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69348</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 examinations described in item 69345 performed on separately collected and identified specimens</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>103.30</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69351</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 examinations described in item 69345 performed on separately collected and identified specimens</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>154.95</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69354</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Blood culture for pathogenic micro-organisms (other than viruses), including sub-cultures and (if performed):</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>identification of any cultured pathogen; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>necessary antibiotic susceptibility testing;</span></p><p class="TableText" style="margin-top:3pt"><span>to a maximum of 3 sets of cultures</span><span> </span><span>— 1 set of cultures</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69357</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 sets of cultures described in item 69354</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>60.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69360</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 sets of cultures described in item 69354</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>90.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69363</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of clostridium difficile or clostridium difficile toxin (except if a service described in item 69345, 69348, 69351, 69369 or 69372 has been performed)</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69366</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Test for </span><span style="font-style:italic">Helicobacter pylori</span><span> in faeces, for either:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the confirmation of </span><span style="font-style:italic">Helicobacter pylori</span><span> colonisation:</span></p><p class="subparatable" style="margin-bottom:3pt"><span style="width:29.57pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:14.2pt; text-indent:0pt; display:inline-block"> </span><span>where suitable biopsy material for diagnosis cannot be obtained at endoscopy in patients with peptic ulcer disease, or where the diagnosis of peptic ulcer has been made on barium meal; or</span></p><p class="subparatable" style="margin-bottom:3pt"><span style="width:26.51pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:14.2pt; text-indent:0pt; display:inline-block"> </span><span>in patients with a history of peptic ulcer disease or gastric neoplasia, where endoscopy is not indicated; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>the monitoring of the success of eradication therapy for </span><span style="font-style:italic">Helicobacter pylori</span><span> in patients with peptic ulcer disease;</span></p><p class="TableText" style="margin-top:3pt"><span>where any request for the test by a medical practitioner specifically identifies in writing one or more of the clinical indications for the test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.10</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69369</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of chlamydia by any method in specimens from 1 or more sites</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>27.80</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69370</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of chlamydia by any method and Neisseria gonorrhoea by nucleic acid amplification techniques in specimens from 1 or more sites</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>32.80</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69372</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of microbial antigens (except if the service described in item 69369 has been performed)</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69375</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination for Herpes simplex virus, varicella zoster virus or cytomegalovirus by culture, including a service described in item 69369 or 69372 (if performed)</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.20</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69378</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of HIV viral RNA load in plasma or serum in the monitoring of a HIV sero-positive patient not on antiretroviral therapy</span><span> </span><span>— 1 or more assays on 1</span><span> </span><span>or more specimens in any 1 episode</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>176.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69381</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of HIV viral RNA load in plasma or serum in the monitoring of antiretroviral therapy in a HIV sero-positive patient</span><span> </span><span>— 1 or more assays on 1</span><span> </span><span>or more specimens in any 1 episode</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>176.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69382</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of HIV viral RNA load in cerebrospinal fluid in a HIV sero</span><span>‑</span><span>positive patient</span><span> </span><span>— 1 or more assays on 1 or more specimens in any 1</span><span> </span><span>episode</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>176.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69384</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Quantitation of 1 antibody to microbial or exogenous antigens not elsewhere described in the Schedule</span><span> </span><span>— 1</span><span> </span><span>test</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.30</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69387</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>2 tests described in item 69384</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69390</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>3 tests described in item 69384</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>42.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69393</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>4 tests described in item 69384</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>56.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69396</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>5 tests described in item 69384</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>70.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69399</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>6 or more tests described in item</span><span> </span><span>69384</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>84.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69402</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Tests described in item 69384, if rendered under a request referred to in subparagraph (2)</span><span> </span><span>(a)</span><span> </span><span>(iii) of rule</span><span> </span><span>6</span><span> </span><span>— each test to a maximum of 5 tests</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>14.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69405</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the determination of 1 of the following</span><span> </span><span>— rubella immune status, specific syphilis serology, hepatitis B surface antigen; and</span></p><p class="paratable"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) a service described in 1 or more of items 69384, 69414 to 69435, 69447 to 69456, 69462 and 69465</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.30</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69408</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the determination of 2 of the following</span><span> </span><span>— rubella immune status, specific syphilis serology or, hepatitis B surface antigen; and</span></p><p class="paratable"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) a service described in 1 or more of items 69384, 69414 to 69435, 69447 to 69456, 69462 and 69465</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>27.15</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69411</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the determination of all 3 of the following</span><span> </span><span>— rubella immune status, specific syphilis serology and Hepatitis B surface antigen; and</span></p><p class="paratable"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) a service described in 1 or more of items 69384, 69414 to 69435, 69447 to 69456, 69462 and 69465</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>38.15</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69414</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for acute Hepatitis A using:</span></p><p class="paratable" style="margin-bottom:3pt; font-size:12pt"><span style="width:25.8pt; text-indent:0pt; display:inline-block"></span><span style="font-size:11pt">Hepatitis A IgM antibody test</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.30</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69417</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Determination of immune status to Hepatitis A using:</span></p><p class="paratable" style="margin-bottom:3pt"><span style="width:25.8pt; text-indent:0pt; display:inline-block"></span><span>Hepatitis A IgG antibody test</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.30</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69420</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for acute or resolving Hepatitis B, or testing of close, recent contacts of proven Hepatitis B infection, including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface antigen test; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B core antibody test; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>if performed, Hepatitis B e antibody test (where the Hepatitis B surface antigen test is negative and Hepatitis B core antibody test is positive)</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>27.15</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69423</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for resolution of Hepatitis B if the Hepatitis B core antibody test is positive and the Hepatitis B surface antigen test is negative, including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B core antibody test; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface antigen test; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface antibody test</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>38.15</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69426</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Determination of immune status to Hepatitis B (post exposure) using:</span></p><p class="paratable" style="margin-bottom:3pt"><span style="width:25.8pt; text-indent:0pt; display:inline-block"></span><span>Hepatitis B core antibody test</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.30</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69429</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Determination of immune status to Hepatitis B (post vaccination) using:</span></p><p class="paratable" style="margin-bottom:2pt"><span style="width:25.8pt; text-indent:0pt; display:inline-block"></span><span>Hepatitis B surface antibody test</span></p><p class="TableText" style="margin-top:2pt"><span>(Item is subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.30</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69432</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for chronic Hepatitis B or determination of carriage of Hepatitis B antigen using:</span></p><p class="paratable" style="margin-bottom:3pt"><span style="width:25.8pt; text-indent:0pt; display:inline-block"></span><span>Hepatitis B surface antigen test</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.30</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69435</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for chronic Hepatitis B or carriage of Hepatitis B antigen if the Hepatitis B surface antigen test is positive, including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface antigen test; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B e antigen test</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>27.15</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69438</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Testing for Hepatitis C using:</span></p><p class="paratable" style="margin-bottom:3pt"><span style="width:25.8pt; text-indent:0pt; display:inline-block"></span><span>Hepatitis C antibody test</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>16.70</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69441</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Supplementary testing for Hepatitis C antibodies using a different Hepatitis C antibody assay on the specimen which has a reactive result on the initial Hepatitis C antibody test</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is not subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>16.70</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69444</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Detection of Hepatitis C viral RNA if at least 1 of the following criteria is satisfied:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the patient is Hepatitis C sero</span><span>‑</span><span>positive and has normal liver function tests on 2 occasions at least 6 months apart;</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>the patient’s serological status is uncertain after testing;</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the test is performed for the purpose of:</span></p><p class="subparatable" style="margin-bottom:3pt"><span style="width:29.57pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:14.2pt; text-indent:0pt; display:inline-block"> </span><span>determining the Hepatitis C status of an immunosuppressed or immunocompromised patient; or</span></p><p class="subparatable" style="margin-bottom:3pt"><span style="width:26.51pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:14.2pt; text-indent:0pt; display:inline-block"> </span><span>the detection of acute Hepatitis C prior to seroconversion where considered necessary for the clinical management of the patient;</span></p><p class="TableText" style="margin-top:3pt; margin-bottom:3pt"><span>not exceeding 1 episode in a 12 month period</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 20)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>90.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69447</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for acute or chronic Hepatitis D in a patient with a positive Hepatitis B surface antigen test using:</span></p><p class="paratable" style="margin-bottom:3pt"><span style="width:25.8pt; text-indent:0pt; display:inline-block"></span><span>Hepatitis D antibody test</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.30</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69450</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Determination of immune status to Hepatitis A and Hepatitis B, including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis A IgG antibody test; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B core antibody test or Hepatitis</span><span> </span><span>B surface antibody test</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>27.15</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69453</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for chronic viral hepatitis, or Hepatitis B or Hepatitis C carriage, including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface antigen test; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis C antibody test</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.55</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69456</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for chronic viral hepatitis, or Hepatitis B or Hepatitis C carriage, if Hepatitis B surface antigen test is positive, including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis C antibody test; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface antigen test; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B e antigen test</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>39.55</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69459</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for acute Hepatitis A, Hepatitis B, Hepatitis C and Hepatitis D in a patient with a currently elevated transaminase level, including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis A IgM antibody test; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis C antibody test; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface antigen test; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(d)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B core antibody test; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(e)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>if performed, Hepatitis B e antibody test (if Hepatitis B surface antigen test is negative and Hepatitis B core antibody test is positive); and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(f)</span><span style="width:14.81pt; text-indent:0pt; display:inline-block"> </span><span>if performed, Hepatitis D antibody test (if Hepatitis B surface antigen test is positive)</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>50.55</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69462</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Determination of immune status to Hepatitis B and testing for Hepatitis C, including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis C antibody test; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B core antibody test or Hepatitis B surface antibody test</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.55</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69465</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Syphilis serology and any 1 of item 69435, 69438 or</span><span> </span><span>69453</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>38.15</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69468</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for acute Hepatitis A and Hepatitis</span><span> </span><span>C in a patient with a currently elevated transaminase level, including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis A IgM antibody test; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis C antibody test</span></p><p class="TableText" style="margin-top:3pt"><span>(Item subject to rule 12)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.20</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69471</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Test of cell</span><span>‑</span><span>mediated immunity in blood for the detection of active tuberculosis or atypical mycobacterial infection in an immunosuppressed or immunocompromised patient</span><span> </span><span>— 1 test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.10</span></p></td></tr><tr><td colspan="4" style="width:357.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="page-break-after:avoid"><span>Group P4</span><span> </span><span>— Immunology</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71057</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Electrophoresis, quantitative and qualitative, of serum, urine or other body fluid all collected within a 28 day period, to demonstrate:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>protein classes; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>presence and amount of paraprotein;</span></p><p class="TableText" style="margin-top:3pt"><span>including the preliminary quantitation of total protein, albumin and globulin</span><span> </span><span>— 1 specimen type</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>35.20</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71058</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination as described in item 71057 of 2 or more specimen types</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>49.85</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71059</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Electrophoresis and immunofixation or immuno electrophoresis or isoelectric focussing of:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>urine for detection of Bence Jones proteins; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>serum, plasma or other body fluid;</span></p><p class="TableText" style="margin-top:3pt"><span>and characterisation, if detected, of a paraprotein or cryoglobulin not previously characterised</span><span> </span><span>— examination of 1 specimen type (eg serum, urine or CSF)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.80</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71060</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination as described in item 71059 of 2 or more specimen types</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71062</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Electrophoresis and immunofixation or immuno electrophoresis or isoelectric focussing of CSF for the detection of oligoclonal bands and including if required electrophoresis of the patient’s serum for comparison purposes</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71064</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection and quantitation of cryoglobulins or cryofibrinogen</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71067</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of total immunoglobulins A, G, M or D by any method in serum, urine or other body fluid</span><span> </span><span>— 1</span><span> </span><span>test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>14.85</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71069</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 71067</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>23.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71071</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 71067</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>32.05</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71073</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of all 4 immunoglobulin G subclasses</span><span> </span><span>— each patient episode</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>104.75</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71075</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of immunoglobulin E (total), with</span><span> </span><span>a</span><span> </span><span>maximum of 2 patient episodes in any 12</span><span> </span><span>month period</span><span> </span><span>— each patient episode</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>26.70</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71077</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of immunoglobulin E (total) in the follow up of a patient with proven immunoglobulin-E-secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis, with a maximum of 6</span><span> </span><span>patient episodes in a 12 month period</span><span> </span><span>— each patient episode</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>26.70</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71079</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of specific immunoglobulin G or E</span><span> </span><span>antibodies to single or multiple potential allergens, with a maximum of 4 patient episodes in a 12 month period</span><span> </span><span>— each patient episode</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>26.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71081</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of total haemolytic complement</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71083</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of complement components C3 and C4 or properdin factor B</span><span> </span><span>— 1 test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.90</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71085</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 71083</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.55</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71087</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 71083</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>37.20</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71089</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this Schedule</span><span> </span><span>— 1 test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.75</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71091</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 71089</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>52.10</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71093</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 71089</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>75.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71095</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of serum or plasma eosinophil cationic protein, or both, to a maximum of 3</span><span> </span><span>assays in 1 year, for monitoring the response to therapy in corticosteroid treated asthma, in a child aged less than 12 years</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71097</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Antinuclear antibodies</span><span> </span><span>— detection in serum or other body fluids, including quantitation if required</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.10</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71099</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Double-stranded DNA antibodies</span><span> </span><span>— quantitation by 1</span><span> </span><span>or more methods other than the Crithidia method</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>26.20</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71101</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Antibodies to 1 or more extractable nuclear antigens</span><span> </span><span>— detection in serum or other body fluids</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.15</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71103</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of an antibody detected in a service described in item 71101 (including that service)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>51.35</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71106</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Rheumatoid factor</span><span> </span><span>— detection by any technique in serum or other body fluids, including quantitation if required</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.15</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71109</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, cardiolipin, glomerular basement membrane, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, neutrophil cytoplasm, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor)</span><span> </span><span>— detection, including quantitation if required, of 1 antibody</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.10</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71113</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 2 antibodies described in item 71109</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>46.80</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71115</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 3 antibodies described in item 71109</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>59.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71117</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 4 antibodies described in item 71109</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>72.20</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71119</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Antibodies to tissue antigens not elsewhere specified in this table</span><span> </span><span>— detection, including quantitation if required, of 1 antibody</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.10</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71121</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 2 antibodies specified in item 71119</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71123</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 3 antibodies specified in item 71119</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>23.90</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71125</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 4 or more antibodies specified in item</span><span> </span><span>71119</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>27.30</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71127</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Functional tests for lymphocytes</span><span> </span><span>— quantitation other than by microscopy of:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>proliferation induced by 1 or more mitogens; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>proliferation induced by 1 or more antigens; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>estimation of 1 or more mixed lymphocyte reactions;</span></p><p class="TableText" style="margin-top:3pt"><span>including a test described in item 65063 or 65066 (if performed), with a maximum of 2 patient episodes in a 12 month period</span><span> </span><span>— each patient episode</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>174.05</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71129</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 71127</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>215.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71131</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 71127</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>255.95</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71135</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Quantitation of neutrophil function, comprising at least</span><span> </span><span>2 of the following:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>chemotaxis;</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>phagocytosis;</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>oxidative metabolism;</span></p><p class="paratable" style="margin-bottom:3pt"><span>(d)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>bactericidal activity;</span></p><p class="TableText" style="margin-top:3pt"><span>including any test described in item 65063 or 65066 (other than nitroblue tetrazolium reduction slide test), with a maximum of 2 patient episodes in a 12 month period</span><span> </span><span>— each patient episode</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>205.25</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71137</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of cell-mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7</span><span> </span><span>antigens, with a maximum of 2 patient episodes in a 12 month period</span><span> </span><span>— each patient episode</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.85</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71139</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count by any method, on 1 or more specimens of blood, CSF or serous fluid</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>102.65</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71141</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>194.80</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71143</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or both of items</span><span> </span><span>71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissue</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>256.60</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71145</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or more of items</span><span> </span><span>71139, 71141 and 71143 (if performed) on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>418.95</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71147</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>HLA-B27 typing</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71149</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Complete tissue typing for 4 HLA-A and HLA-B Class</span><span> </span><span>I antigens (including any separation of leucocytes), including (if performed) a service described in item</span><span> </span><span>71147</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>106.85</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71151</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Tissue typing for HLA-DR, HLA-DP and HLA</span><span>‑</span><span>DQ Class II antigens (including any separation of leucocytes)</span><span> </span><span>— phenotyping or genotyping of 2 or more antigens</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>117.30</span></p></td></tr><tr><td colspan="4" style="width:357.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="page-break-after:avoid"><span>Group P5 — Tissue pathology</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72813</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Examination of complexity level 2 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1</span><span> </span><span>or more separately identified specimens</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 14)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>79.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72816</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1</span><span> </span><span>separately identified specimen</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 14)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>84.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72817</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 2</span><span> </span><span>or more separately identified specimens</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 14)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>94.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72823</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1</span><span> </span><span>separately identified specimen</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 14)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>95.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72824</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 2</span><span> </span><span>to 4 separately identified specimens</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 14)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>138.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72825</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 5</span><span> </span><span>or more separately identified specimens</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 14)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>176.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72830</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Examination of complexity level 5 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1</span><span> </span><span>or more separately identified specimens</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 14)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>160.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72836</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Examination of complexity level 6 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1</span><span> </span><span>or more separately identified specimens</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 14)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>190.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72844</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Enzyme histochemistry of skeletal muscle for investigation of primary degenerative or metabolic muscle diseases or of muscle abnormalities secondary to disease of the central or peripheral nervous system</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72846</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 1 to 3 antibodies</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 14)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>42.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72847</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 4 or more antibodies</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 14)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>56.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72851</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Electron microscopic examination of biopsy material</span><span> </span><span>— 1 separately identified specimen</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 14)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>180.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72852</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Electron microscopic examination of biopsy material</span><span> </span><span>— 2 or more separately identified specimens</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 14)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>240.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72855</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Intraoperative frozen section diagnosis of biopsy material</span><span> </span><span>— 1 separately identified specimen</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 14)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>180.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72856</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Intraoperative frozen section diagnosis of biopsy material</span><span> </span><span>— 2 or more separately identified specimens</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to rule 14)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>240.00</span></p></td></tr><tr><td colspan="4" style="width:357.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="page-break-after:avoid"><span>Group P6</span><span> </span><span>— Cytology</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73043</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.80</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73045</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73053); and including any Group P5 service (if performed) on:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>specimens resulting from washings or brushings from sites not specified in item</span><span> </span><span>73043; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>a single specimen of sputum or urine; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>1 or more specimens of other body fluids;</span></p><p class="TableText" style="margin-top:3pt"><span>1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>45.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73047</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology of a series of 3 sputum or urine specimens for malignant cells</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>90.00</span></p></td></tr><tr><td style="width:53.1pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73049</span></p></td><td colspan="2" style="width:244.75pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>65.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73051</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues, if:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the aspiration is performed by a recognised pathologist; or</span></p><p class="paratable"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>a recognised pathologist attends the aspiration and performs a cytological examination during the attendance</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>163.85</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73053</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Cytology of smears from cervix:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>for detection of precancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>due to an unsatisfactory smear taken in the circumstances defined in paragraph (a) above; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>if there is inadequate information provided to use item 73055;</span></p><p class="TableText" style="margin-top:3pt"><span>each examination</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>18.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73055</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Cytology not associated with item 73053, of smears from cervix in association with:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>the management of previously detected abnormalities including precancerous or cancerous conditions; or</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia;</span></p><p class="TableText" style="margin-top:3pt"><span>each test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>18.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73057</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology of smears from vagina, not associated with item 73053 or 73055 nor to monitor hormone replacement therapy</span><span> </span><span>— each test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>18.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73059</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 1 to 3 antibodies</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>42.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73060</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 4 or more antibodies</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>56.00</span></p></td></tr><tr><td colspan="4" style="width:357.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="page-break-after:avoid"><span>Group P7 — Cytogenetics</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73287</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Chromosome studies, including preparation, count, karyotyping and identification by banding techniques or fragile X-site determination of 1 or more of any tissue or fluid except blood</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>354.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73289</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Chromosome studies, including preparation, count, karyotyping and identification by banding techniques or fragile X-site determination of blood</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>322.00</span></p></td></tr><tr><td colspan="4" style="width:357.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="page-break-after:avoid"><span>Group P8 — Infertility and pregnancy tests</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73521</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner’s test)</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73523</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Semen examination (other than post-vasectomy semen examination), including:</span></p><p class="paratable" style="margin-bottom:3pt"><span>(a)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>measurement of volume, sperm count and motility; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(b)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>examination of stained preparations; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(c)</span><span style="width:13.59pt; text-indent:0pt; display:inline-block"> </span><span>morphology; and</span></p><p class="paratable" style="margin-bottom:3pt"><span>(d)</span><span style="width:12.97pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) differential count and 1 or more chemical tests;</span></p><p class="TableText" style="margin-top:3pt"><span>with a maximum of 4 episodes in a 12 month period</span><span> </span><span>— each episode</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>41.20</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73525</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Sperm antibodies</span><span> </span><span>— sperm-penetrating ability</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73527</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Human chorionic gonadotrophin (HCG)</span><span> </span><span>— detection in serum or urine by 1 or more methods, including serial dilution (if performed) for diagnosis of pregnancy</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.90</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73529</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Human chorionic gonadotrophin (HCG), quantitation in serum by 1 or more methods (except by latex, membrane, strip or other pregnancy test kit) for diagnosis of threatened abortion, or follow up of abortion or diagnosis of ectopic pregnancy, including any services performed in item 73527</span><span> </span><span>— 1 test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.25</span></p></td></tr><tr><td colspan="4" style="width:357.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="page-break-after:avoid"><span>Group P9 — Simple basic pathology tests</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73801</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Semen examination for presence of spermatozoa</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>6.75</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73802</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count</span><span> </span><span>— 1 test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>4.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73803</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 73802</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>6.20</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73804</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 73802</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>7.95</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73805</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy of urine, whether stained or not, or catalase test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>4.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73806</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Pregnancy test by 1 or more immunochemical methods</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.90</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73807</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy for wet film other than urine, including any relevant stain</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>6.75</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73808</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy of Gram-stained film, including (if performed) a service described in item 73805 or 73807</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>8.45</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73809</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>2.30</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73810</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy for fungi in skin, hair or nails</span><span> </span><span>— 1 or more sites</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>6.75</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73811</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Mantoux test</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.95</span></p></td></tr><tr><td colspan="4" style="width:357.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="page-break-after:avoid"><span>Group P10</span><span> </span><span>— Patient episode initiation</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73901</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode that consists only of a service described in item 73053, 73055 or 73057 from a person who is not in a recognised hospital or a prescribed laboratory</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>8.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73903</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode that consists only of 1 or more services described in items 72813, 72816, 72817, 72823, 72824, 72825, 72830 and 72836 from a person who is an in-patient of a hospital other than a recognised hospital</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>14.30</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73905</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode that consists only of 1 or more services described in items 72813, 72816, 72817, 72823, 72824, 72825, 72830 and 72836 from a person who is not an in-patient of a private hospital and not a patient of a recognised hospital</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>8.00</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73907</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected in a licensed collection centre</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.15</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73909</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person who is an in-patient of a hospital other than a recognised hospital</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.15</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73910</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in the place where the person was residing</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.50</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73912</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in a nursing home or institution</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.15</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73913</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905, 73907 or items in Group</span><span> </span><span>P9) if the specimen is collected from the person by the person</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.10</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73915</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or items in Group P9) if the specimen is collected by or on behalf of the treating practitioner</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.10</span></p></td></tr><tr><td colspan="4" style="width:357.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="page-break-after:avoid"><span>Group P11</span><span> </span><span>— Specimen referred</span></p></td></tr><tr><td colspan="2" style="width:53.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73921</span></p></td><td style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Receipt of a specimen by an approved pathology practitioner of an approved pathology authority from another approved pathology practitioner of a different approved pathology authority or another approved pathology authority</span></p><p class="TableText" style="margin-top:3pt"><span>(Item is subject to subrules 15</span><span> </span><span>(9) and 17</span><span> </span><span>(3))</span></p></td><td style="width:38.65pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.50</span></p></td></tr><tr style="height:0pt"><td style="width:63.8pt"></td><td style="width:0.3pt"></td><td style="width:255.15pt"></td><td style="width:49.35pt"></td></tr></tbody></table>
Part 2Services and fees

Get a plain-English read of Part 2
